Key result
Thymosin β4 treatment significantly reduced myocardial infarct size to 15% compared to 25% in untreated mice (p=0.02) and improved cardiac function following myocardial infarction.
Why the study?
Does Thymosin beta4 improve cardiac function and reduce infarct size in a mouse model of myocardial infarction via the PIP-Akt pathway?
Does Thymosin beta4 improve cardiac function and reduce infarct size in a mouse model of myocardial infarction via the PIP-Akt pathway?
Absolute Event Rate: 15% vs 25%
p-value: p=0.02
Thymosin β4 improves cardiac function and reduces fibrosis post-myocardial infarction by enhancing PIP-mediated Akt activation and suppressing NF-κB.
No takes yet. Share an insight, caveat, or question.
Supports thymosin β4 investigation in murine MI; leaves open human translation pending trials.
Sopko et al. (2011) studied Dilated Cardiomyopathy and Myocardial Infarction. Thymosin beta4 vs. PBS (untreated MI) was evaluated on Infarct size at 7 days post-myocardial infarction (p=0.02). Thymosin β4 treatment significantly reduced myocardial infarct size to 15% compared to 25% in untreated mice (p=0.02) and improved cardiac function following myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: